Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical characteristics and outcomes of lung cancer patients  with EGFR mutations in exons 19 and 21].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 1 Nov 2014

Liu Renwang, Liu Jinghao, Li Xin, Li Ying, Zhao Qingchun, Li Zuosheng, Liu Hongyu, Chen Jun

Abstract excerpt

BACKGROUND AND OBJECTIVE: Studies on the epidermal growth factor receptor (EGFR) signaling pathways and the therapeutic effects of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have recently proven that targeted therapy has a major role in the treatment of lung cancer. However, the therapeutic effects of EGFR-TKIs on lung cancers with different EGFR mutation subtypes remain unclear. And if there is a significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Sex Factors

Share to Smoking

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 25404271
DOI: 10.3779/j.issn.1009-3419.2014.11.06
PMCID: PMC6000356

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical characteristics and outcomes of lung cancer patients with EGFR mutations in exons 19 and 21].PMID 25404271Read ↗

Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.Semantic proximity Read ↗

Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review)Semantic proximity Read ↗

Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancerSemantic proximity Read ↗

The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China.Semantic proximity Read ↗

[Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].Semantic proximity Read ↗

[Exon 19 Deletion and Exon 21 L858R Point Mutation in EGFR Mutation‒Positive Non‒Small Cell Lung Cancer].Semantic proximity Read ↗

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21Semantic proximity Read ↗

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer.Semantic proximity Read ↗

Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.Semantic proximity Read ↗

Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung cancerSemantic proximity Read ↗

Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.